Reimund J M, Duclos B, Baumann R
Service d'Hépato-Gastroentérologie et d'Assistance Nutritive, Hôpitaux Universitaires de Strasbourg, Hôpital de Haute-pierre.
Ann Med Interne (Paris). 1997;148(8):527-9.
Cyclosporin has been suggested as an alternative treatment in severe acute ulcerative colitis. In a retrospective study, the outcome of seven ulcerative colitis patients treated by intravenous cyclosporin (mean dose 3.6 mg/kg/day) has been evaluated. Short-term results indicated full remission in 3/7 (43%) patients. At long term follow-up (one year), only 2/7 patients could avoid ileal pouch-anal anastomosis. Two complications (one colonic perforation and one septicemia) were observed. Our results suggest that intravenous cyclosporin should not be recommended as a standard therapy in severe acute ulcerative colitis. Its use has to be limited in patients presenting a major contraindication for surgery and has to be performed by those experienced in both immunosuppressive treatment and inflammatory bowel disease.
环孢素已被建议作为重度急性溃疡性结肠炎的一种替代治疗方法。在一项回顾性研究中,对7例接受静脉注射环孢素(平均剂量3.6毫克/千克/天)治疗的溃疡性结肠炎患者的治疗结果进行了评估。短期结果显示,3/7(43%)的患者实现了完全缓解。在长期随访(一年)中,只有2/7的患者能够避免回肠储袋肛管吻合术。观察到两例并发症(一例结肠穿孔和一例败血症)。我们的结果表明,静脉注射环孢素不应被推荐作为重度急性溃疡性结肠炎的标准治疗方法。对于存在手术主要禁忌证的患者,其使用必须受到限制,并且必须由在免疫抑制治疗和炎症性肠病方面都有经验的人员进行操作。